Home > Rheumatology > ACR 2020 > How to Diagnose Large Vessel Vasculitis: Promises and Pitfalls > Diagnosis of large vessel vasculitis with imaging

Diagnosis of large vessel vasculitis with imaging

Presented By
Dr Peter Grayson, National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, USA
Conference
ACR 2020

Imaging plays an important role in establishing the diagnoses of both Takayasu’s arteritis and giant cell arteritis. The landscape of possibilities is evolving, and the advantages and disadvantages of different investigations have to be weighed.

In large vessel vasculitis, it is important to understand the limitations of traditional evaluations and to know in what way inflammation may be recognised on different imaging modalities [1]. This talk focused more on the disease entities of Takayasu’s arteritis and giant cell arteritis which share many pathological similarities.

Takayasu’s arteritis is a disease that presents with many different imaging faces. In terms of choosing between the different possible types of angiography that may be performed to diagnose Takayasu’s, Dr Peter Grayson (National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, USA) reflected on several considerations. In general, he rated CT angiography (CTA) and magnetic resonance angiography (MRA) as equivalent. An advantage for the MRA is of course the avoidance of radiation which can be particularly valuable in younger patients. Another aspect to consider in MRA is possible long retention of gadolinium that has been found in different tissues. In any case, Dr Grayson endorsed avoidance of catheter-based angiographies and measurement of central artery pressure in Takayasu’s disease.

The use of temporal artery biopsies (TAB) to diagnose giant cell arteritis (GCA) can also be seen as a medal with 2 sides: on the plus-side, there is tissue-level confirmation, documented findings with a possibility for direct review, and the historically accepted role of TAB as the gold standard. Limitations of TAB include the possibility of missing skip lesions, some cases of CGA in which the temporal arteries are not affected, and the fact that TAB is invasive, expensive, and open to subjective interpretation. Dr Grayson also mentioned that the sensitivity of temporal artery biopsy is declining. He pointed out that large vessel GCA –an increasingly recognised phenotype– may or may not have cranial features of the disease. It includes on one hand less risk for vision loss, but on the other risk for more relapsing and refractory disease. Currently, multi-modal assessment in GCA is being performed in many parts of the world (see Figure). In a large study with 941 GCA patients, 25% had no TAB, 27% of TABs were negative, and 47% positive.

Figure. Use of multi-modal assessments in the diagnosis of GCA [1]

GCA, giant cell arteritis; TAB, temporal artery biopsies; TA-US, temporal artery ultrasound; LV, large vessel.

In summary, Dr Grayson made recommendations for diagnostic imaging in patients with (suspected) GCA, stressing the fact that these were all conditional: TAB is endorsed over temporal artery ultrasound and MRI of cranial arteries. In case of negative biopsy, non-invasive large vessel imaging can aid in diagnosis over clinical assessment alone. Finally, in newly diagnosed GCA, non-invasive vascular imaging can be of help in evaluating large vessel involvement.

  1. Grayson P. Large Vessel Vasculitis Imaging: Promises and Pitfalls. 2F053, ACR Convergence 2020, 5-9 Nov.


Posted on